Selumetinib is the first FDA-approved treatment for inoperable plexiform neurofibroma in patients with neurofibromatosis 1 that seeks to induce anti-tumor activity by inhibiting the MEK pathway [18,19,20]. This evidence concerns the gene MAP2K7 and plexiform neurofibroma.